NCT07304518
Recruiting
Phase 2
Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase II Trial of PRT-064040 Nasal Spray for the Acute Treatment of Migraine
Sichuan Purity Pharmaceutical Technology Co., Ltd.1 site in 1 country456 target enrollmentStarted: January 26, 2026Last updated:
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Sichuan Purity Pharmaceutical Technology Co., Ltd.
- Enrollment
- 456
- Locations
- 1
- Primary Endpoint
- Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Overview
Brief Summary
The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and female participants aged 18-75 years (inclusive);
- •BMI \< 35 kg/m²;
- •Participant has at least 1-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition;
- •Age at first migraine onset \< 50 years;
- •Migraine attacks, on average, lasting about 4-72 hours if untreated or treatment-resistant;
- •2-8 attacks of moderate to severe intensity per month within the last 3 months；
- •Less than 15 days with headache (migraine or non-migraine) per month within the last 3 months；
- •Participants on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change until the EOT visit;
- •Patients diagnosed with chronic migraine who, owing to stable preventive therapy, have \< 15 headache days and 2-8 attacks of moderate to severe intensity per month in the 3 months before screening, and who meet all other entry criteria, may be enrolled;
- •Able to comprehend and complete study questionnaires with electronic patient-reported outcome (e-PRO) application.
Exclusion Criteria
- •Participant with history of migraine with brainstem aura, retinal migraine, or hemiplegic migraine.
- •Participant with evidence of poorly controlled, unstable, or recently diagnosed cardiovascular or cardiometabolic disease, or prior history thereof, including:
- •Ischemic heart disease, coronary vasospasm, or cerebral ischemia diagnosed within 6 months before screening;
- •Previous stroke, transient ischemic attack, myocardial infarction, acute coronary syndrome, cardiac surgery, or percutaneous coronary intervention;
- •Abnormal 12-lead ECG at screening;
- •Poorly controlled diabetes mellitus or hypertension;
- •Poorly controlled or severe peripheral vascular disease.
- •Participant with any nasal structural abnormality, mucosal lesion, or disorder that could interfere with intranasal drug absorption.
- •Participant with dysgeusia, hypogeusia, or related taste disorders.
- •Participant with acute or chronic pain syndromes, or any other pain that in the investigator's opinion could confound study assessments.
Arms & Interventions
PRT-064040 nasal spray (dose 1)
Experimental
Participants administered a single intranasal dose of PRT-064040 nasal spray (dose 1) on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.
Intervention: PRT-064040 nasal spray (Drug)
PRT-064040 nasal spray (dose 2)
Experimental
Participants administered a single intranasal dose of PRT-064040 nasal spray (dose 2) on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.
Intervention: PRT-064040 nasal spray (Drug)
PRT-064040 nasal spray (dose 3)
Experimental
Participants administered a single intranasal dose of PRT-064040 nasal spray (dose 3) on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.
Intervention: PRT-064040 nasal spray (Drug)
Placebo
Experimental
Participants administered a single intranasal dose of placebo on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.
Intervention: Placebo (Drug)
Outcomes
Primary Outcomes
Percentage of Participants With Freedom From Pain at 2 Hours Post-dose
Time Frame: 2 hours post-dose
Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose
Time Frame: 2 hours post-dose
Secondary Outcomes
- Percentage of Participants With Pain Relief at 15 Minutes Post-dose(15 minutes post-dose)
- Percentage of Participants With Pain Relief at 30 Minutes Post-dose(30 minutes post-dose)
- Percentage of Participants With Pain Relief at 60 Minutes Post-dose(60 minutes post-dose)
- Percentage of Participants With Pain Relief at 2 Hours Post-dose(2 hours post-dose)
- Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose(2 hours post-dose)
- Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose(From 2 to 24 hours post-dose)
- Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose(From 2 to 48 hours post-dose)
- Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose(30 minutes post-dose)
- Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose(60 minutes post-dose)
- Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose(2 hours post-dose)
- Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose(2 hours post-dose)
- Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose(2 hours post-dose)
- Percentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose(From 2 to 24 hours post-dose)
- Percentage of Participants With Sustained Pain Freedom From 2 Hours to 48 Post-dose(From 2 to 48 hours post-dose)
- Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose(From 2 hours to 48 hours post-dose)
- Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose(Through 24 hours post-dose)
- Percentage of Participants Who Were Able to Function Normally at 15 Minutes Post-dose(15 minutes post-dose)
- The incidence and severity of adverse events(Through 7(±2) days post-dose)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Not Applicable
Evaluation of Bactorinol® Nasal Spray in Adult Patients With Vasomotor RhinitisNCT07266688Liaquat University of Medical & Health Sciences100
Active, not recruiting
Phase 2
PRT-064040 鼻喷雾剂Ⅱ期临床试验CTR20254825456
Completed
Phase 1
PRT-064040 鼻喷雾剂在健康受试者中的临床研究CTR2025204080
Not yet recruiting
Not Applicable
Nebulized Nasal SteroidsNCT07270302Washington University School of Medicine50
Completed
Phase 2
JT002（曾用名 IAMA-001）治疗成人季节性过敏性鼻炎的 II 期研究CTR20250089320